A Phase 3 interventional study of Tinlarebant and Placebo in Stargardt Disease 1, sponsored by Belite Bio, Inc. Completed at 19 sites in 11 countries. Open to participants aged 12 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Belite Bio, Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Stargardt Disease with a site in United States — 16 open to participants now, 25 under way, 3 of them phase 3. Stargardt Disease · United States.
Among the 42 studies in Stargardt Disease with a site in United States, this one is the 8th largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2022, is one of 3 in phase 3, and was the 23rd registered.
68 studies on the registry are indexed under Stargardt Disease; 27 are open to participants now.
Browse Stargardt Disease studies →16 of the 42 studies in Stargardt Disease with a site in United States are open now. Recruiting first, the newest first:
Astellas Institute for Regenerative Medicine · Sites in United States
Ages 6+
Alkeus Pharmaceuticals, Inc. · Sites in United States
Ages 8–45
Cellio Therapeutics Inc · Sites in United States
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in United States
Ages 6+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Stargardt Disease studies recruiting now, 15 (63%) set no upper age limit and 7 (29%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.
This study: 12 Years to 20 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 16 · Phase 3 5
First in 2003; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 104 is above the median of 30 across 43 interventional studies indexed under Stargardt Disease.
Median enrollment 41 across the 26 interventional studies, 63 across the 16 observational. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 42 have an industry lead sponsor. The 10 most frequent:
Belite Bio, Inc is the lead sponsor of 4 studies on the registry; none are open to participants now.
Belite Bio, Inc has 2 studies filed under Stargardt Disease — fewer than ten, so there is no comparison to draw.
6 of the studies in Stargardt Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06435000Splice BioAn Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene | 2026-12 |
| NCT07502664Ray Therapeutics, Inc.Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD) | 2027-02 |
| NCT06048185Nanoscope Therapeutics Inc.Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study | 2027-05 |
| NCT06591806AAVantgarde Bio SrlAn Observational Study in Children and Adults With Stargardt Disease | 2027-06-30 |
| NCT03011541MD Stem CellsStem Cell Ophthalmology Treatment Study II | 2027-07-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 42 studies in Stargardt Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this trial is to assesses the efficacy of tinlarebant in slowing the rate of growth of atrophic lesion(s) in adolescent subjects with STGD1
Approximately 90 subjects will be enrolled in this study. Subjects will be assigned to study drug (tinlarebant 5 mg/placebo) with treatment period of upto 24 months with 28 days of follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 mg tablet taken orally once a day
Drug: Tinlarebant
Placebo tablets for tinlarebant 5 mg are prepared similarly but use microcrystalline cellulose, NF, in place of the active drug substance and will be identical in size and appearance.
Drug: Placebo
Tinlarebant drug substance is a white to off-white substance and is dispensed as a tablet for oral administration.
Not active drug
To measure change in atrophic lesion size (definitely decreased autofluorescence, DDAF) by fundus autofluorescence (FAF) photography from baseline
Time frame: Baseline thru month 24
To measure the change in retinal thickness assessed by spectral-domain optical coherence tomography (SD-OCT) from baseline
Time frame: Baseline thru month 24
To measure the change in retinal morphology assessed by spectral-domain optical coherence tomography (SD-OCT) from baseline
Time frame: Baseline thru month 24
To measure change in BCVA (Best Corrected Visual Acuity) score measured by the EDTRS method from baseline
Time frame: Baseline thru month 24
To measure change in plasma concentration of RBP4 levels (μM) from baseline
Time frame: Baseline thru month 24
The correlation between change in plasma RBP4 level and the rate of lesion size growth (definitely decreased autofluorescence, DDAF) by fundus autofluorescence (FAF) photography from baseline
Time frame: Baseline thru month 24
To assess the systemic and ocular safety and tolerability of tinlarebant
Frequency, duration, and severity of AEs
Time frame: Baseline thru month 24
To measure change in total decreased autofluorescence (DAF) by FAF photography from baseline
Time frame: Baseline thru month 24
To measure change in questionably decreased autofluorescence (QDAF) by FAF photography from baseline
Time frame: Baseline thru month 24
To measure change in quantitative autofluorescence (qAF) level from baseline
Time frame: Baseline thru month 24
To measure change in retinal sensitivity by microperimetry from baseline
Time frame: Baseline thru month 24
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2022 to primary completion in Aug 2025, 40 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tinlarebant
Belite Bio, Inc